Showing 2341-2350 of 5771 results for "".
- Allergan and Molecular Partners Announce Topline Safety Results From MAPLE Study of Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/2476430/Allergan and Molecular Partners announced topline safety results from MAPLE, a 28-week open-label study which enrolled 123 age-related neovascular macular degeneration (AMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, trea
- NovaBay Pharmaceuticals Announces Investments of $5 Million to Support US Avenova Commercialization Strategyhttps://modernod.com/news/novabay-pharmaceuticals-announces-investments-of-5-million-to-support-us-avenova-commercialization-strategy/2476424/NovaBay Pharmaceuticals announced investments totaling $5 million to support the recent strategic shift in its US commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness. The investments include a convertible loan of $2 million from Ascendia
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys With Transitions Light Intelligent Technology in the U.S.https://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-u-s/2479584/Johnson & Johnson Vision announced the US availability of Acuvue Oasys with Transitions Light Intelligent Technology. The contact lenses adapt to changing light, helping eyes recover from bright light up to 5 seconds faster, reducing halos and starbursts at night, and delivering more sight w
- Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-initiation-of-phase-2b-clinical-study-of-csf-1-for-the-treatment-of-presbyopia/2476421/Orasis Pharmaceuticals announced the initiation of a phase 2b clinical study in the United States evaluating CSF-1 for the treatment of presbyopia. The phase 2b study is a multicenter, double-masked trial in the United States enrolling 150 participants with presbyopia to evaluate the efficacy and
- Aldeyra Therapeutics Announces Positive Results From Phase 3 Allergic Conjunctivitis Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-the-phase-3-alleviate-trial-in-patients-with-allergic-conjunctivitis/2476416/Aldeyra Therapeutics announced positive results from the phase 3 ALLEVIATE trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary and the key secondary endpoint for both concentrations of reproxalap. “We a
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b
- ReNeuron Announces Retinal Clinical Trial Progresses to Next Stagehttps://modernod.com/news/reneuron-announces-retinal-clinical-trial-progresses-to-next-stage/2476391/ReNeuron Group has announced a further update on progress with the ongoing phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in retinitis pigmentosa (RP). The company reported that, following a positive Data Safety Monitoring Board (DSMB) review of the clinical data fro
- Iconic NYC Eyewear Retailers Announced for Guided Tourshttps://modernod.com/news/iconic-nyc-eyewear-retailers-announced-for-guided-tours/2476383/Vision Expo has announced the addition of several iconic and innovative eyewear retailers to its new Retail Store Tours taking place during Vision Expo East 2019. Each tour provides attendees the opportunity to go behind-the-scenes and hear directly from store ambassadors for some of the world’s
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti
- Prevent Blindness Announces Recipient of 2019 Jenny Pomeroy Award for Excellence in Vision and Public Healthhttps://modernod.com/news/prevent-blindness-announces-recipient-of-2019-jenny-pomeroy-award-for-excellence-in-vision-and-public-health/2476374/Prevent Blindness has announced the recipient of the 2019 Jenny Pomeroy Award for Excellence in Vision and Public Health is Cynthia Owsley, PhD, MSPH, Nathan E. Miles Chair of Ophthalmology and Director of the Clinical Research Unit at the University of Alabama at Birmingham (UAB) School of Medic